Oct. 28 at 5:22 PM
$CVKD Recent acquisition of Frunexian went unnoticed… worth looking into before it gets picked up https://x.com/stockpicksnyc/status/1983221836050514213?s=12
It’s currently the only IV small-molecule Factor XIa inhibitor in active development exclusively targeting acute indications
Phase 2-ready, multi-billion dollar market opportunity
https://pmc.ncbi.nlm.nih.gov/articles/PMC10983022/
“Frunexian, a potent and selective small molecule FXIa inhibitor, demonstrated selective and effective inhibition of the intrinsic coagulation pathway, desirable pharmacokinetics, and safety profile in this Phase I clinical trial.”
“Frunexian administration in healthy Chinese volunteer adults exhibits favorable safety profiles with no bleeding events, predictable PK, and dose‐proportional PD.”
The CVKD acquisition of frunexian also includes EP-7327, an oral Factor XIa inhibitor, for the prevention and treatment of major thrombotic conditions.
